Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
 & Lead Plaintiff Deadline: June 19, 2017 - EconoTimes)
NEW YORK, May 10, 2017 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NYSE:TXMD) securities and certain of its officers, on behalf of a class who purchased TherapeuticsMD securities between July 7, 2016 and April 9, 2017, (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/txmd.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that the TherapeuticsMD’s New Drug Application (“NDA”) submission for TX-004HR was deficient and was not supported by the complete TX-004HR clinical program, which would likely cause a delay of the Food & Drug Administration’s potential approval of the NDA. On April 10, 2017, the Company announced that the U.S. Food & Drug Administration had found deficiencies in its NDA for TX-004HR.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/txmd or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in TherapeuticsMD you have until June 19, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
